Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Express Scripts
Covington
Farmers Insurance
Deloitte
Boehringer Ingelheim
Colorcon
Harvard Business School

Generated: April 27, 2018

DrugPatentWatch Database Preview

APRACLONIDINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

When do Apraclonidine Hydrochloride patents expire, and what generic alternatives are available?

Apraclonidine Hydrochloride is a drug marketed by Akorn Inc and is included in one NDA.

The generic ingredient in APRACLONIDINE HYDROCHLORIDE is apraclonidine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apraclonidine hydrochloride profile page.
Summary for APRACLONIDINE HYDROCHLORIDE
Drug patent expirations by year for APRACLONIDINE HYDROCHLORIDE
Pharmacology for APRACLONIDINE HYDROCHLORIDE
Synonyms for APRACLONIDINE HYDROCHLORIDE
1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-, monohydrochloride
1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-2-imidazolidinylidene-, monohydrochloride
2-((4-Amino-2,6-dichlorophenyl)imino)imidazolidine monohydrochloride
2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride
2-(4-Amino-2,6-dichlorophenylimino)imidazolidine hydrochloride
2-[(2,6-dichloro-4-aminophenyl)imino]imidazolidine hydrochloride
2,6-bis(chloranyl)-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride
2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride
2,6-Dichloro-N(1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride
2,6-Dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride
2,6-Dichloro-N(sup 1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride
2,6-Dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride
2,6-Dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine Hydrochloride
2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride
218A798
3,5-Dichloro-4-(2-imidazolidinylidenimino)aniline hydrochloride
4CH-016312
73218-79-8
87913-86-8
A 0779
A837749
AC-12705
AC1L1BOD
AK143283
AKOS022175501
AKOS025401362
AL 02145
AL-02145
ALO-2145
AN-6532
Aplonidine HCl
Aplonidine hydrochloride
Apraclonidine hydrochloride
Apraclonidine HCl
Apraclonidine hydrochloride (JAN/USP)
Apraclonidine hydrochloride [USAN]
Apraclonidinehydrochloride
BG0575
C-17735
C9H10Cl2N4.HCl
C9H11Cl3N4
CAS-73218-79-8
CC-24163
CCG-221337
CHEBI:2789
CHEMBL1200379
CTK8F7806
D01008
D2VW67N38H
DR000985
DSSTox_CID_25749
DSSTox_GSID_45749
DSSTox_RID_81093
DTXSID6045749
EU-0100033
FT-0602878
Iopidine ophthalmic solution
KS-00000MLM
LP00033
LS-29586
MFCD00135922
MLS000028829
MLS006010230
MolPort-006-069-427
NC 14 hydrochloride
NCGC00093552-01
NCGC00260718-01
OTQYGBJVDRBCHC-UHFFFAOYSA-N
p-Aminoclonidine hydrochloride
p-Aminoclonidine hydrochloride, solid
p-Aminoclonidine Monohydrochloride
S311
SCHEMBL41138
SMR000058965
SR-01000075247
SR-01000075247-1
ST2409192
Tox21_111207
Tox21_500033
UNII-D2VW67N38H

US Patents and Regulatory Information for APRACLONIDINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn Inc APRACLONIDINE HYDROCHLORIDE apraclonidine hydrochloride SOLUTION/DROPS;OPHTHALMIC 077764-001 Mar 12, 2009 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
UBS
Chinese Patent Office
Teva
Accenture
US Department of Justice
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.